remedē System
Commercial- Indications
- Central Sleep Apnea
Company intelligence / Profile preview
ZOLL Respicardia
Minnetonka, Minnesota, United Statesremede.zoll.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Commercial
01
Overview
The remedē System is an FDA-approved implantable neurostimulation device for treating moderate to severe central sleep apnea in adults. Clinical trials published in The Lancet demonstrated significant reduction in CSA severity, improved sleep quality, and enhanced patient well-being. The system is commercially available and covered by major insurers.
- Therapeutic areas
- Pulmonology
- Modalities
- DeviceNeurostimulator
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 asset03
Partnerships
SelectHealth insurance coverage partnership for the remedē System
Beyond the preview
Go deeper on ZOLL Respicardia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZOLL Respicardia.